Quoin Pharmaceuticals, Ltd. (QNRX)
| Market Cap | 3.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.70M |
| Shares Out | 5.05M |
| EPS (ttm) | -2.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,026 |
| Open | 0.640 |
| Previous Close | 0.633 |
| Day's Range | 0.610 - 0.661 |
| 52-Week Range | 0.477 - 6.180 |
| Beta | 1.89 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+539.39%) |
| Earnings Date | Nov 7, 2024 |
About QNRX
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consult... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for QNRX stock is "Strong Buy" and the 12-month stock price forecast is $4.0.
News
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan disea...
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for...
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announce...
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening additiona...
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan disea...
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan disea...
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late ...
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseas...
Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical ...
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan dise...
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin P...
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed...
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan disea...
REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints
Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q2 2023 Results Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Cha...
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results
Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study
Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan disea...
Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman, Chie...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
First patient dosed in Quoin's single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy
Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET
ASHBURN, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseas...